The Spanish pharmaceutical company Rovi has completed the purchase of a drug manufacturing plant in Phoenix , Arizona, from Bristol Myers Squibb (BMS), after finalizing all the procedures stipulated in the contract signed months ago. With this move, the Madrid-based group consolidates its industrial expansion strategy and takes another step to strengthen its international presence in the injectable products segment.
According to a statement released by the company to the Spanish National Securities Market Commission (CNMV) , the transaction was completed after the usual conditions for this type of deal were met and it was confirmed that no significant adverse changes had occurred since the initial agreement was signed. The transaction includes the Phoenix plant, as well as various assets and liabilities related to the pharmaceutical manufacturing activity carried out at the facility, which was previously managed by BMS.
Details of the agreement between Rovi and Bristol Myers Squibb
The contract signed between Rovi and Bristol Myers Squibb, initially announced last September, establishes a minimum duration of five years from the effective closing of the transaction. During that period, a minimum payment of $50 million annually (approximately €46,5 million) has been set as part of the manufacturing agreement between the two companies.
As part of this transaction, Rovi has formalized a long-term manufacturing agreement with BMS , under which its subsidiary Rois Phoenix will continue producing medications for the US multinational at its Arizona plant. This agreement governs the terms of service, production volumes, quality standards, and the maintenance of the necessary resources to ensure the factory remains fully operational, retaining the essential personnel required for its functioning.
The continued production for BMS means that, at least during these initial years, the plant will not only be integrated into Rovi's industrial network but will also maintain a close relationship with its former owner. This ensures a stable workload for the Spanish pharmaceutical company from day one , a crucial factor when incorporating a large facility into its structure.
Rovi has emphasized to the market that the transaction has not been affected by any significant events since its announcement, allowing it to meet the established deadlines for completing the contract. Both the standard authorizations and the necessary technical and regulatory checks for the asset transfer have been successfully completed, ensuring the orderly integration of the Phoenix plant into the group.
A "state-of-the-art" plant to strengthen the manufacturing network
The Spanish company has described the Phoenix factory as a state-of-the-art facility , equipped with advanced technology for the production of injectable medications. The addition of this plant expands Rovi's existing industrial network, operating in various locations, primarily in Spain and Europe, and significantly increases its production capacity for these types of products.
By integrating these facilities, Rovi aims to expand its contract manufacturing services offering, a business in which it already has a significant presence within the European sector. The added capacity in the United States allows the pharmaceutical company to have a more geographically diversified industrial platform , which can facilitate agreements with new partners and improve access to customers located both in North America and in other international markets.
The company emphasizes that the new plant strengthens its strategic alliances and helps bolster the supply of injectable medications, a particularly sensitive segment in terms of quality, delivery times, and security of supply. In a context where weaknesses have been identified in global pharmaceutical production chains, having a broader and more flexible industrial network is considered a key competitive advantage.
Furthermore, the acquisition aligns with Rovi's roadmap, which has been developing in recent years to consolidate its position as a key player in the contract manufacturing of high value-added products . The company combines its own portfolio of pharmaceuticals with a growing contract manufacturing business, leveraging specialized and certified facilities for demanding markets such as the European Union and the United States.
Boost to the high value-added injectables business
Rovi has emphasized that this acquisition is a strategic move within its medium- and long-term growth plan. The aim is to strengthen its position in the high-value-added injectables segment , which includes formats such as pre-filled syringes , cartridges, and vials, all of which have stringent technical and regulatory requirements.
The company has been investing in this type of presentation, not only due to its growing demand in complex therapies, but also because of the value it brings in terms of industry differentiation. Having increased capacity at an advanced plant like the one in Phoenix allows Rovi to take on new development and production projects, both for its own medications and for international partners seeking specialized and reliable manufacturing.
From a European perspective, this move reinforces Rovi's role as a continental leader in the manufacture of injectables , combining a solid industrial base in Spain with a strengthened presence in the United States. This dual geographic footprint can be particularly relevant when negotiating agreements with large pharmaceutical groups that require suppliers with global capabilities and consistent quality standards across different regions.
The acquisition could also have an indirect impact on Rovi's operations in Europe, as greater global capacity allows for the redistribution of production, optimization of workloads across plants, and offers its European customers more supply options and greater flexibility . In a sector where long-term planning is key, having a broad industrial network can make all the difference.
Closing conditions and regulatory security
In the communication sent to the Spanish stock market regulator, Rovi explains that the contract was finalized once the customary closing conditions for corporate transactions of this type were met. These included the necessary technical, financial, and regulatory verifications to ensure that the transfer of the plant and associated assets was carried out with full guarantees.
The pharmaceutical company also emphasizes that since the initial agreement was signed, no significant adverse events have occurred that would materially affect the transaction value or the plant's prospects. This was a key clause in the contract, and its fulfillment has allowed the transaction to proceed to closing without substantial changes from the initial plan.
The fact that the transaction was completed smoothly sends a message of stability to the market and Rovi's industrial partners. The continuity of production for Bristol Myers Squibb through Rois Phoenix, along with the retention of the necessary staff, helps ensure that the plant maintains its service level while being progressively integrated into the systems and processes of the Spanish group.
Overall, the purchase of the Phoenix plant consolidates Rovi's strategy to gain size and weight in the injectable drug manufacturing business, combining international expansion with long-term collaboration agreements that ensure production volume, customer diversification, and a greater presence in key markets such as the US and Europe.